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Department of Gynecology and Obstetrics, Comprehensive Cancer Center, Medical University of Vienna, Vienna, AustriaAbstractAn investigational monovalent human papillomavirus (HPV) 16 virus-like particle vaccine has been shown to prevent persistent infection and
cervical disease related to HPV 16 and was proof of concept (2002). Designed to prevent the bulk of invasive cervical cancer, quadrivalent
(HPV 6/11/16/18) and bivalent (HPV 16/18) vaccines have been available since 2006 and 2007, respectively. They are highly effective in
preventing HPV 16/18–related cervical precancer; the quadrivalent version also prevents genital warts related to HPV 6/11. It has been
shown that the precursors of vulvar, vaginal and anal cancer related to the vaccine types are effectively prevented. This led to a paradigm
shift from a female-only cervical cancer vaccine to a vaccine for the prevention of HPV-related disease and cancer for both sexes.
Vaccination before the start of sexual activity is most effective, and consequently most programs target 9- to 12-year-olds. Additionally,
recent studies have proven the noninferior immunoresponse of a two-dose schedule in these age cohorts. Gender-neutral vaccination
has become more common; it improves coverage and also provides protection to all males. Recently a nine-valent HPV vaccine (HPV 6/
11/16/18/31/33/45/52/58) was licensed; it provides high and consistent protection against infections and diseases related to these types,
with ~90% of cervical and other HPV-related cancers and precancers potentially being avoided. Coverage is key. Efforts must be made to
provide HPV vaccination in low-resource countries that lack screening programs. In countries with cervical cancer screening, HPV
vaccination will greatly affect screening algorithms.
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E-mail: elmar.joura@meduniwien.ac.atIntroductionThe connection between persistent infection with human
papillomavirus (HPV) and cervical cancer was ﬁrst described by
Harald zur Hausen in 1977 [1]. He was later awarded the Nobel
Prize for physiology or medicine. This ﬁnding laid the ground
for the idea of a vaccine against HPV infection and cervical
cancer, and in 1999 it ﬁnally became clear that persistent HPV
infection is a necessary cause of invasive cervical cancer [2].
Cervical cancer is the second most common cancer in women
worldwide; the majority of cases involves younger women inClinical Microbiology and Infection © 2015 European Society of Cless developed countries. The burden of the disease worldwide
was estimated at more than 585 000 incident cases and more
than 380 000 deaths in 2010 [3].Monovalent HPV 16 vaccineAlthough the development of vaccines against diseases like hep-
atitis C and human immunodeﬁciency virus failed, the develop-
ment of an HPV vaccine has been successful. The L1 protein self-
assembled to a virus-like particle (VLP) was highly immunogenic
[4,5]. The L1 protein is HPV type speciﬁc, and hence the pro-
tection is mainly type speciﬁc. Structural analogies also enable
cross-reactive antibodies; there is a close relationship between
HPV 16 and 31 and between HPV 18 and 45. In 1998, a landmark
trial with 2400 women aged 16 to 23 years, and a HPV 16 L1 VLP
vaccination program (the same composition later used in the
quadrivalent HPV vaccine) was started. After a median follow-upClin Microbiol Infect 2015; 21: 827–833
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neoplasia (CIN) related to HPV 16 were prevented by this vac-
cine [6]. This was the proof of principle that oncogenic infections
and cancer precursors related to themost potent oncogenicHPV
strainmay be preventable. During the follow-up of this trial, it was
demonstrated that HPV 16–related high-grade CIN can be pre-
vented for up to 9.5 years [7,8].Quadrivalent HPV (qHPV) 6/11/16/18 vaccineAfter a successful phase 2 trial [9,10], the pivotal phase 3 trials
of the qHPV vaccine started in 2002 (V501; Females United to
Unilaterally Reduce Endo-/Ectocervical Disease (FUTURE)
Study I/II). This vaccine targeted the HPV strains responsible for
approximately 70% of cervical cancers and 90% of genital warts.
The FUTURE trials included more than 17 000 young women
aged 16 to 26 years. The efﬁcacy in the per-protocol analyses
against cervical disease related to HPV 16 and 18 was 97% to
100% in these trials [11–13].
It became clear that this high efﬁcacy was only achieved in a
prophylactic situation in women not infected with the relevant
HPV type at the time of vaccination and did not go far beyond the
types included in the vaccine. The quadrivalent vaccine was
licensed by the US Food and Drug Administration (FDA) in 2006
and marketed by Merck & Co. (USA) as Gardasil and Silgard.Bivalent HPV (bHPV) vaccineA second HPV vaccine primarily focused on cervical cancer
only, so the studies had only clinical end points of cervical
disease and were only conducted with female subjects. The
bHPV is composed of C-terminally truncated HPV 16 + 18 L1
VLPs and adjuvanted with a novel aluminium salt (AS04). This
compound is responsible for eliciting a strong immune
response. In a head-to-head comparison of the bHPV and the
qHPV vaccines, higher antibody levels were demonstrated for
bHPV. However, no clinical end points were investigated [14].
No lower threshold of antibody level after vaccination has yet
been established; even in seronegative subjects, no break-
through disease has been observed after vaccination [15]. The
bHPV has demonstrated a per-protocol efﬁcacy against CIN 2+
lesions related to HPV 16/18 of 92.9% to 100% [16,17]. In
addition, a reduction of CIN 2+ lesions related to HPV 31 and
33 was observed [18]. A reduction of CIN 3, irrespective of
HPV type, in a subset of HPV-naive women of 93% is likely to be
driven by the efﬁcacy against HPV 16/18/31/33; in the same
analyses, the reduction of any CIN 2+ was 56.2% [18,19]. TheClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectbHPV is marketed as Cervarix (GSK, UK) and was licensed in
Europe in 2007 and in the United States in 2009.Duration of protectionCurrently both vaccines show a good long-term protection of
up to 10 years. The qHPV is being followed in an extension of
the FUTURE II trial in the Nordic countries, and no break-
through disease related to HPV 16/18 has been observed for up
to 10 years (Kjaer, paper presented at Eurogin 2015). The
phase 2 trials of bHPV have been evaluated up to 9.4 years, with
100% efﬁcacy against infection with HPV 16 or 18 [20,21].
Robust long-term protection beyond 10 years can be expected
for both vaccines.Protection against noncervical diseaseGenital warts (GW)
GW are a common condition affecting both women and men,
with a peak in the early third decade of life. The lifetime risk is
in the order of 10% and the prevalence 1% [22]. GW are not
life-threatening, but they are a severe limitation to quality of life.
In contrast to cancer, the outbreak of the disease occurs only a
few months after infection. HPV 6 and 11 are the most com-
mon low-risk HPV strains and account for 85% of GW; 30% of
GW involve coinfection with high-risk HPV types [23]. This
results in an increased risk for subsequent HPV-related disease
[24]. The efﬁcacy of the qHPV against GW related to the
vaccine types in young women aged 16 to 26 was 99% in the
per-protocol populations of the FUTURE trials [25] and in
young men 90% [26]. In the intention-to-treat analyses, the
efﬁcacy against GW, irrespective of HPV type, was 82% in HPV-
naive women; when including those with prior HPV infections,
the efﬁcacy was still 62% [25].
Vulvovaginal disease
During the past decades, an increasing incidence of high-grade
vulvar intraepithelial neoplasias and invasive vulvar cancer has
been observed in various parts of the world [27–29]. The
observed increased incidence is mainly reported in younger
women as a result of HPV infection, whereas in the older cohorts
the incidence remains stable because these vulvar neoplasms are
not HPV related. This disease is mainly attributed to HPV 16, and
today 25% to 40%of invasive vulvar cancers are attributed toHPV
[30,31]. In the largest available series of invasive vaginal cancers,
74% were HPV related and comprised 96% of precancers. These
lesions are predominantly related to HPV 16.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 827–833
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grade vulvar/vaginal intraepithelial neoplasias related to HPV
16 and 18 was 100%, and 79% in the intention-to-treat popu-
lation [32,33].
Anal disease
Anal cancer affects both sexes and is more common in female
subjects. An increasing incidence has been reported; men who
have sex with men (MSM) are at the highest individual risk, in
particular when they are positive for human immunodeﬁciency
virus. This was the reason why the efﬁcacy of qHPV was
evaluated in a substudy including 602 MSM. In the intention-to-
treat cohort, the efﬁcacy was 54% and 75% in the per-protocol
analysis. The corresponding rates against infection with the
vaccine types were 59% and 95% [34]. In the Costa Rica trial
with bHPV, the reduction of anal HPV 16/18 infections was 62%
to 84%, depending on the analysed cohort, 4 years after
vaccination [35].
Oropharyngeal disease
An epidemiologic change is currently ongoing. While the inci-
dence of the classical oropharyngeal cancer is declining, HPV-
related oropharyngeal cancer is on the rise. Forty percent of
oropharyngeal cancers are related mainly to HPV 16, pre-
dominantly affect male subjects and are going to exceed the
numbers of cervical cancers in the United States in the next few
years [36,37]. HPV-related oropharyngeal cancers have a better
prognosis than those that are HPV negative; however, the
treatment is followed by signiﬁcant long-term morbidity [38].
No data on HPV vaccination and oropharyngeal cancers are
available. In the Costa Rica trial with bHPV, oral HPV 16 in-
fections were signiﬁcantly reduced by 92% in the vaccinated
cohort [39].
Low-risk types HPV 6 and 11 cause juvenile-onset respira-
tory papillomatosis; vertical transmission in women with
maternal GW is the main risk factor. This disease is rare but
leads to signiﬁcant impaired quality of life as a result of the need
to undergo repeated surgical treatments. Small case series
suggest that the interval between these surgeries may be
extendable through vaccination, but the lack of randomization
and the quasi-experimental study designs makes these data hard
to interpret. Because HPV 6 antibodies can be detected in the
umbilical cord blood of infants, vaccinated mothers may protect
their children [40].Vaccination of adultsBoth HPV vaccines are prophylactic, and early vaccination,
preferably before exposure, is therefore most efﬁcient. This hasClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyalso been demonstrated in real-life experience. However, both
vaccines have been shown to be effective in preventing
persistent infections and cervical lesions up to the age of 45
years [41,42]. The vaccines per se have no therapeutic effect,
but it was demonstrated that female and male subjects vacci-
nated with the quadrivalent vaccine have fewer recurrent HPV-
related diseases [24,43–45].Real-life experienceAustralia was the ﬁrst country to set up a broad HPV vaccination
program. Starting in 2007, Australia offered vaccination to all
schoolgirls at the age of 12 to 13 yearswith a catch-up programup
to the age of 26 years. They achieved coverage of approximately
86% for one dose, and up to 73% received all three doses. At just 3
years after the onset of this program, a signiﬁcant decline in the
incidence of GW was observed; meanwhile, GW were close to
being eradicated in young women. This was followed by a decline
in the incidence of GW in boys and men as a result of herd
protection. No effect was observed in MSM [46,47]. This decline
inGWwas followed by a decline in high-grade cervical lesions and
cytologic abnormalities [48,49]. Notably, there was a proven
reduction of new infections with vaccine-related viruses. It was
demonstrated that the rate of HPV infections was reduced in the
vaccine-eligible age cohorts [50,51].
Similar reductions have been observed in European coun-
tries. In Denmark, high vaccine coverage is combined with high-
quality registries. This results in a detailed picture of vaccine
efﬁcacy. In the birth cohorts 1993–1994, vaccinated women
had a reduced risk of GW (relative risk (RR) 0.22) and CIN 3
(RR 0.20) [52,53]. In the United States, a 72% reduction of HPV
16/18–related CIN 2+ was observed 4 years or more after
vaccination [54]. The United States, Australia and Denmark use
qHPV; the United Kingdom used bHPV from 2008 onwards. In
England, a highly signiﬁcant reduction of HPV 16/18 prevalence
was observed in the age group of 16 to 18 years, with 65%
coverage: from 19.1% to 6.5%. There was no signiﬁcant dif-
ference in the nonvaccine types. In the age cohort 19 to 21
years (44% coverage), the reduction of HPV 16/18 prevalence
dropped from 17.4% to 12.5%. In 2012, England switched to
qHPV because the protection against GW makes HPV vacci-
nation even more effective—as well as cost-effective. In Scot-
land, a 90% or higher coverage with bHPV was achieved; a
signiﬁcant reduction in diagnoses of CIN 3 (RR 0.45) for
women who received three doses of vaccine compared with
unvaccinated women was observed [55]. In summarizing the
ﬁndings of various countries, it is obvious that the effectiveness
of the vaccination program depends on coverage and age. The
earlier girls are vaccinated, the fewer cases are observed later.and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 827–833
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the target population. Herd protection can only be seen in
countries with a good coverage, as in Australia. In countries with
less coverage, gender-neutral vaccination is a way to improve
coverage and effectively interrupt virus circulation. In such a
scenario, it is considered to be cost-effective. However, there are
more arguments than coverage and cost-effectiveness. It is also a
political question of equality. Boys and men have a substantial
burden of HPV-related diseases; they have a right to personal
protection. There is no reason to burden only girls and women
with responsibility. Also, a female-only vaccination program
provides no protection toMSM,who have amarked risk [46].On
the basis of these considerations, Australia, the United States,
Canada and Austria, as well as some Italian regions and Saxony,
Germany, have introduced gender-neutral vaccination [56].
Switzerland and Ireland recommend vaccination of boys, and the
United Kingdom and Greece recommend vaccination for MSM.Two-dose scheduleThe studies for clinical efﬁcacy for both vaccines have been
performed in young women utilizing a three-dose schedule
(qHPV 16 to 26 years, 0/2/6 months; bHPV 15 – 25 years, 0/1/6
months). The immunogenicity in the target cohorts of young girls
and boys has been evaluated. It demonstrated superior antibody
levels compared to young women, especially in the 9-to-11-year-
old age group [57]. This was the basis of the licensure for this age
group. Many countries with an imperfectly organized vaccination
program struggle with the application of the third dose. In the
United States, the coverage for the ﬁrst dose in girls was 57% and
for the third dose was 38%; the corresponding ﬁgures for boys
were 35% and 14% in 2013 [58]. After incidental observations in
the Costa Rica trial that two or even one dose are effective
[59,60], systematic trials with two doses have been performed
with both vaccines. In girls aged 9 to 13/14 years, the antibody
levels after two doses were higher than in young adult women
after three doses [61–63], but only after an interval of at least 6
months between the two shots. This has been observed for at
least 36 (qHPV) and 48 (bHPV) months. The World Health Or-
ganization recommends a two-dose schedule for children up to
the age of 15 unless they are immunocompromised. The Euro-
pean health authorities (European Medicines Agency) have
licensed both vaccines for a two-dose application with a sug-
gested interval of 6 to 12 months. The interval is key; if a three-
dose schedule is started and the third dose is simply forgotten,
the immune response is inferior [64].Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectNine-valent HPV vaccineAfter the quadrivalent vaccine was available, the next step was to
prevent disease with the next ﬁve most common oncogenic HPV
types, HPV 31/33/45/52/58. These types account for 90% of the
immediate precursors of cervical cancer (CIN 3 and
adenocarcinoma-in-situ) and for 90% of invasive cervical cancers
globally [3,65,66]. For other HPV-related cancers, the incre-
mental beneﬁt is in the order of 5% to 15%, and for cervical
invasive cancer or precancer (i.e. CIN grade 2 or worse) 20% and
35%, respectively [67]. For both available vaccines, some cross-
protection has been reported; however, after reduction of
coinfections with HPV 16/18, the effect appeared to bemoderate
and not long lasting [18,68]. Hence, a robust protection against
persistent infection and disease related to the most dangerous
types is needed. The most dangerous types for development of
CIN 3 or cancer have been described in an analysis of a trial on
HPV typing in 47 000 women. HPV 16/18/31/33/52/45 persistent
infections confer the highest risk for CIN 3 or cancer [69].
After extensive dose-ranging studies, a noninferior immu-
nogenicity and protection against HPV 6/11/16/18 was a regu-
latory prerequisite [70]. The pivotal phase 3 trial began in 2009.
Because effective vaccines were available, a placebo-controlled
trial was not possible for ethical reasons; the control group thus
received qHPV. More than 14 200 young women aged 16 to 26
years participated; the inclusion and exclusion criteria were the
same as in the qHPV trials [11]. They were followed in total up
to 54 months; the analysis which was the basis for FDA
approval was case driven. Noninferiority was achieved for HPV
6/11/16/18, and the efﬁcacy against persistent infection and
disease caused by HPV 31/33/45/52/58 was >96% [71]. For the
target populations of the 9- to 15-year-old boys and girls,
bridging studies were performed; as expected, higher antibody
levels were seen in the younger population (VanDamme, paper
presented at Eurogin 2013). On 10 December 2014 the FDA
licensed the nine-valent vaccine for use in girls and women aged
9 to 26 years and for boys aged 9 to 15 years (Gardasil 9; Merck
& Co.). Data on boys and men up to the age of 26 have been
presented (Castellsagué, paper presented at Eurogin 2015). A
study investigating a two-dose schedule is ongoing. Application
of the new vaccine in prior qHPV recipients is safe and
immunogenic. Coadministration with Repevax or Menactra has
been investigated; it is safe and does not induce an inferior
immunoresponse [72]. No protection beyond the vaccine types
was observed; the vaccine fully met expectations and showed
robust and consistent protection against infection and disease
caused by the nine HPV types in every analysis. The safety
proﬁle of the new vaccine was favourable; in all study protocols,
more than 13 000 subjects received nine-valent HPV. Inious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 827–833
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observed, as expected, as a result of the higher amount of
antigen; systemic reactions were comparable. There were very
few study discontinuations due to vaccine-related adverse
events (Moreira, paper presented at Eurogin 2015).Conclusion and perspectivesAlthough HPV vaccines were originally developed as a cervical
cancer vaccine for adolescent girls, signiﬁcant changes in
vaccination paradigms can be observed. HPV vaccination has
become a protection against a broad spectrum of HPV-related
diseases and cancers affecting both sexes. It has become clear
that early vaccination before exposure provides the best results
and that a two-dose schedule, which is easier to distribute and
saves money, appears to be noninferior to the three-dose
regimen. Female-only concepts for the prevention of cervical
cancer are feasible with high coverage, but boys and men should
have the right to personal protection. Gender-neutral vacci-
nation would improve the protection of boys and men in
general, including MSM. Protection is best administered long
before sexual orientation becomes overt. For these reasons,
countries like Australia, the United States and Austria have
already introduced a gender-neutral vaccination. Countries and
continents with a high incidence of and mortality due to cervical
cancer usually do not have a screening in place, and in these
countries, HPV vaccination—and even more with the nine-
valent vaccine—have the potential to control and even elimi-
nate this devastating disease.
We have a global responsibility to put major efforts into
broad HPV vaccination. The Global Alliance for Vaccination and
Immunization (GAVI) has demonstrated that a reasonable price
and wide distribution can be achieved. Projects in countries like
Rwanda and Bhutan have demonstrated that a well-organized,
school-based program can achieve excellent coverage, sur-
passing that of most industrialized countries, where antivaccine
activists question any vaccination projects; measles outbreaks in
Europe and the United States, rather than measles eradication,
are the direct result of this attitude. In countries with screening
programs, the prevention of abnormal Papanicolaou tests and
treatments for precancerous lesions will lower costs. In addi-
tion, HPV vaccination will prevent preterm deliveries and
neonatal mortality by preventing cervical surgeries (loop elec-
trosurgical excision procedure, conization) [73].
The future of cervical cancer screening will be HPV testing,
which has much better sensitivity compared to Papanicolaou
testing, and with type-speciﬁc HPV tests, the speciﬁcity is
comparable. In the United States, primary HPV screening is
considered to be an alternative to Papanicolaou testing andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologycotesting [74]. The Netherlands and Australia plan to replace
Papanicolaou testing with primary HPV testing in 2016. In
vaccinated populations, HPV screening is superior, may start
later in life and will demand fewer tests over the course of a
lifetime. In those who have acquired infections or who have
been treated for HPV-related disease, secondary prevention is
possible. In the future, even earlier vaccination with perhaps a
single dose could improve coverage and protection on a
population-level basis [75]. Today, achieving good coverage is
key, and major efforts must be put into this task. The new nine-
valent HPV vaccine is the next milestone along the road [76].Transparency declarationBoth authors report no conﬂicts of interest relevant to this
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